The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 10, 2024

Filed:

Mar. 23, 2018
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Inventors:

Antonia Wallrapp, Boston, MA (US);

Samantha J. Riesenfeld, Cambridge, MA (US);

Patrick R. Burkett, Boston, MA (US);

Monika S. Kowalczyk, Cambridge, MA (US);

Aviv Regev, Cambridge, MA (US);

Vijay K. Kuchroo, Boston, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/20 (2006.01); A61K 9/00 (2006.01); A61K 38/22 (2006.01); A61P 37/08 (2006.01); C12Q 1/6883 (2018.01);
U.S. Cl.
CPC ...
A61K 38/20 (2013.01); A61K 9/0073 (2013.01); A61K 38/22 (2013.01); A61P 37/08 (2018.01); C12Q 1/6883 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract

Computational and functional analysis identified the neuropeptide receptor Nmur1 as selectively expressed on Type 2 innate lymphoid cells (ILC2s). While both IL-33 and IL-25 promote ILC activation in vivo, IL-33 induces robust ILC proliferation, whereas ILCs activated with IL-25 do not proliferate as robustly and up-regulate Nmur1 expression. Treatment with neuromedin U (NMU), the neuropeptide ligand of Nmur1, had little effect on its own. Co-administration of IL-25 with NMU, however, dramatically amplified allergic lung inflammation and induced the proliferation and expansion of specific ILC2 subsets, characterized by a molecular signature unique to pro-inflammatory ILC2s. The results demonstrate that Nmur1 signaling strongly modulates IL-25-mediated ILC2 responses, resulting in highly proliferative pro-inflammatory ILCs, and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces.


Find Patent Forward Citations

Loading…